<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333550</url>
  </required_header>
  <id_info>
    <org_study_id>1398.1224</org_study_id>
    <nct_id>NCT04333550</nct_id>
  </id_info>
  <brief_title>Application of Desferal to Treat COVID-19</brief_title>
  <official_title>Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kermanshah University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kermanshah University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be
      treated with standard treatment regimens in combination with IV injection of Deferoxamine.
      Improvement in clinical, laboratory and radiological manifestations will be evaluated in
      treated patient compared to control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 20 days</time_frame>
    <description>All cause of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in patients clinical manifestation</measure>
    <time_frame>up to 20 days</time_frame>
    <description>Mild, Moderate or Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in patients PaO2</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>up to 20 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte count</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of intensive care unit stay</measure>
    <time_frame>1 to 20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental: Desferal addition to standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <description>Intravenous infusion of Deferoxamine</description>
    <arm_group_label>Experimental: Desferal addition to standard treatment</arm_group_label>
    <arm_group_label>Experimental: standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of COVID-19 Disease,

        Exclusion Criteria:

        Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yadollah Shakiba, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amir Kiani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alireza Ghaffarieh, MD</last_name>
    <phone>+1-608-698-7334</phone>
    <email>alirezaghaffariyeh@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yadollah Shakiba, MD, PhD</last_name>
    <email>yshakiba@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</name>
      <address>
        <city>Kermanshah</city>
        <zip>083</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yadollah Shakiba, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008 Jul;6(7):541-52. doi: 10.1038/nrmicro1930. Review.</citation>
    <PMID>18552864</PMID>
  </results_reference>
  <results_reference>
    <citation>Nairz M, Haschka D, Demetz E, Weiss G. Iron at the interface of immunity and infection. Front Pharmacol. 2014 Jul 16;5:152. doi: 10.3389/fphar.2014.00152. eCollection 2014. Review.</citation>
    <PMID>25076907</PMID>
  </results_reference>
  <results_reference>
    <citation>Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis. 2000 Feb;181(2):484-90.</citation>
    <PMID>10669330</PMID>
  </results_reference>
  <results_reference>
    <citation>Vlahakos D, Arkadopoulos N, Kostopanagiotou G, Siasiakou S, Kaklamanis L, Degiannis D, Demonakou M, Smyrniotis V. Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. Artif Organs. 2012 Apr;36(4):400-8. doi: 10.1111/j.1525-1594.2011.01385.x. Epub 2011 Dec 21.</citation>
    <PMID>22187937</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang H, Li Z, Niu J, Xu Y, Ma L, Lu A, Wang X, Qian Z, Huang Z, Jin X, Leng Q, Wang J, Zhong J, Sun B, Meng G. Antiviral effects of ferric ammonium citrate. Cell Discov. 2018 Mar 27;4:14. doi: 10.1038/s41421-018-0013-6. eCollection 2018.</citation>
    <PMID>29619244</PMID>
  </results_reference>
  <results_reference>
    <citation>Cinatl J Jr, Cinatl J, Rabenau H, GÃ¼mbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res. 1994 Sep;25(1):73-7.</citation>
    <PMID>7811060</PMID>
  </results_reference>
  <results_reference>
    <citation>Visseren F, Verkerk MS, van der Bruggen T, Marx JJ, van Asbeck BS, Diepersloot RJ. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest. 2002 Mar;32 Suppl 1:84-90.</citation>
    <PMID>11886437</PMID>
  </results_reference>
  <results_reference>
    <citation>Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses. 1995 Sep;11(9):1049-61.</citation>
    <PMID>8554902</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang HC, Bayeva M, Taiwo B, Palella FJ Jr, Hope TJ, Ardehali H. Short communication: high cellular iron levels are associated with increased HIV infection and replication. AIDS Res Hum Retroviruses. 2015 Mar;31(3):305-12. doi: 10.1089/aid.2014.0169. Epub 2014 Oct 7.</citation>
    <PMID>25291189</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyer D. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload. Curr Pharm Des. 2006;12(16):1943-7. Review.</citation>
    <PMID>16787239</PMID>
  </results_reference>
  <results_reference>
    <citation>Cinatl J, Scholz M, Weber B, Cinatl J, Rabenau H, Markus BH, Encke A, Doerr HW. Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. Transpl Immunol. 1995 Dec;3(4):313-20.</citation>
    <PMID>8665150</PMID>
  </results_reference>
  <results_reference>
    <citation>Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther. 1999 Jan;81(1):53-75. Review.</citation>
    <PMID>10051178</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinberg GA. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May;38(5):997-1003.</citation>
    <PMID>8067783</PMID>
  </results_reference>
  <results_reference>
    <citation>Paradkar PN, De Domenico I, Durchfort N, Zohn I, Kaplan J, Ward DM. Iron depletion limits intracellular bacterial growth in macrophages. Blood. 2008 Aug 1;112(3):866-74. doi: 10.1182/blood-2007-12-126854. Epub 2008 Mar 27.</citation>
    <PMID>18369153</PMID>
  </results_reference>
  <results_reference>
    <citation>Giannakopoulou E, Pardali V, Zoidis G. Metal-chelating agents against viruses and parasites. Future Med Chem. 2018 Jun 1;10(11):1283-1285. doi: 10.4155/fmc-2018-0100. Epub 2018 May 3. Review.</citation>
    <PMID>29719970</PMID>
  </results_reference>
  <results_reference>
    <citation>Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, Biemba G, Msiska R, Holmes L, McKinley E, et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med. 1992 Nov 19;327(21):1473-7.</citation>
    <PMID>1406879</PMID>
  </results_reference>
  <results_reference>
    <citation>Duchemin JB, Paradkar PN. Iron availability affects West Nile virus infection in its mosquito vector. Virol J. 2017 Jun 5;14(1):103. doi: 10.1186/s12985-017-0770-0.</citation>
    <PMID>28583206</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kermanshah University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr. Yadollah Shakiba</investigator_full_name>
    <investigator_title>Dr. Yadollah Shakiba, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COVID-19, Deferoxamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

